Harbor Investment Advisory LLC Sells 1,350 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Harbor Investment Advisory LLC trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 23.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,455 shares of the company’s stock after selling 1,350 shares during the quarter. Harbor Investment Advisory LLC’s holdings in CRISPR Therapeutics were worth $175,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRSP. American Century Companies Inc. increased its position in CRISPR Therapeutics by 4.0% in the 2nd quarter. American Century Companies Inc. now owns 18,411 shares of the company’s stock valued at $994,000 after buying an additional 703 shares in the last quarter. Dimensional Fund Advisors LP increased its position in CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after buying an additional 19,094 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in CRISPR Therapeutics by 4.3% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 10,787 shares of the company’s stock valued at $583,000 after buying an additional 447 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in CRISPR Therapeutics by 13.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,167 shares of the company’s stock valued at $225,000 after buying an additional 486 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new stake in CRISPR Therapeutics in the 2nd quarter valued at about $1,449,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Stock Up 6.5 %

CRSP opened at $44.20 on Thursday. The stock has a market cap of $3.77 billion, a PE ratio of -15.62 and a beta of 1.68. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10. The business’s fifty day simple moving average is $44.43 and its 200 day simple moving average is $47.88.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the firm earned ($1.41) earnings per share. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Barclays decreased their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. JMP Securities reissued a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Chardan Capital reissued a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Bank of America decreased their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $78.38.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.